QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=D5F715532E1964E76539017D11BBDCAC;jsessionid=3F7151879880A3C9575406FF75D67AB2;jsessionid=2424C02A698F9BA85EFB8C97AEB6392A;jsessionid=CD896F40545E36619E0465283086E3E9;jsessionid=58A1C04BFA2848C5BC75663912A9F272;jsessionid=78E2E4821F4341A40340A7BAD5C9A8A6 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=D5F715532E1964E76539017D11BBDCAC;jsessionid=3F7151879880A3C9575406FF75D67AB2;jsessionid=2424C02A698F9BA85EFB8C97AEB6392A;jsessionid=CD896F40545E36619E0465283086E3E9;jsessionid=58A1C04BFA2848C5BC75663912A9F272;jsessionid=78E2E4821F4341A40340A7BAD5C9A8A6